Table 4.
Characteristics of the population according to the diagnosis of steatohepatitis.
| Non-Steatohepatitis (N 102) |
Steatohepatitis (N 89) |
p | |
|---|---|---|---|
| Age, years | 12.9 (1.6) | 13.1 (1.8) | 0.40 |
| Sex, (F/M) | 57/45 | 46/43 | 0.79 |
| BMI, kg/sqm | 26.8 (4.2) | 28.3 (4.4) | 0.01 |
| WC, cm (IQR) | 85.9 (72–95) | 90 (80–99) | 0.02 |
| Uric acid, mg/dL | 5.4 (1.6) | 6 (1.4) | 0.01 |
| ALT, UI/L (IQR) | 49 (24–66) | 75 (39–90) | 0.001 |
| AST, UI/L (IQR) | 37 (25–45) | 50 (33–62) | 0.001 |
| GGT, UI/L (IQR) | 21 (13–24) | 30 (19–38) | 0.04 |
| Total-cholesterol, mg/dL (IQR) | 158 (93–175) | 161 (78–183) | 0.22 |
| HDL, mg/dL (IQR) | 44 (37–49) | 47 (35–48) | 0.70 |
| Triglycerides, mg/dL (IQR) | 100 (73–138) | 127 (74–146) | 0.04 |
| Glucose, mg/dL (IQR) | 80 (75–86) | 89 (76–96) | 0.03 |
| Insulin, μUI/ML (IQR) | 17 (10–24) | 24 (18–32) | 0.02 |
| HOMA-IR (IQR) | 3.5 (2.2–4.5) | 4.6 (3.2–6.2) | 0.001 |
| DBP, mmHg (IQR) | 65 (58–72) | 68 (61–75) | 0.08 |
| SBP, mmHg (IQR) | 110 (101–118) | 114 (103–121) | 0.31 |
| TNF-a, pg/mL | 44 (7.5–44) | 72 (12–72) | 0.02 |
| IL-6, pg/mL | 25 (22–35.5) | 35 (15–39) | 0.048 |
| GH, ng/mL (IQR) | 7.5 (6–8.2) | 5.4 (4–6.8) | 0.001 |
| IGF1, ng/mL(IQR) | 284 (208–345) | 245 (150–310) | 0.01 |
| IGFBP-3, µg/mL (IQR) | 2.6 (1.6–3.4) | 2 (1.4–2.8) | 0.02 |
BMI = Body Mass Index; WC = Waist Circumference; AST = aspartate aminotransferase; ALT = alanine aminotransferase; GGT = gamma-glutamyl transferase; HDL = High Density Lipoprotein; HOMA-IR = HOmeostasis Model Assessment-estimated Insulin Resistance; DBP = Diastolic Blood Pressure; SBP = Systolic Blood Pressure; GH = Growth Hormone; IGF1 = Insulin-like Growth Factor 1; IGFBP-3 = Insulin-like Growth Factor-Binding P Correlation of GH, IGF1 and IGFBP-3 with metabolic parameters and histology.